The exact etiology of cholangiocarcinoma remains undetermined. One of the related risk factors for its development might be chronic viral hepatitis infection. Concerning hepatitis B infection, a correlation with cholangiocarcinoma has been documented. Here, we summarize knowledge on the prevalence of hepatitis B seropositivity among patients with cholangiocarcinomas. According to the literature review, five reports were recruited for further metanalysis, covering 565 cases. The overall prevalence of seropositive cancer was 14.5 % (83/ 565). Further analysis revealed no correlation between prevalence rate and nationality of the studied population (P > 0.05). Therefore, hepatitis B infection might be a contributing factor for cholangiocarcinoma development.
(2005). Seroprevalence of Hepatitis Virus B Seropositive in the Patients with Cholangiocarcinoma: a Summary. Asian Pacific Journal of Cancer Prevention, 6(1), 27-28.
MLA
. "Seroprevalence of Hepatitis Virus B Seropositive in the Patients with Cholangiocarcinoma: a Summary". Asian Pacific Journal of Cancer Prevention, 6, 1, 2005, 27-28.
HARVARD
(2005). 'Seroprevalence of Hepatitis Virus B Seropositive in the Patients with Cholangiocarcinoma: a Summary', Asian Pacific Journal of Cancer Prevention, 6(1), pp. 27-28.
VANCOUVER
Seroprevalence of Hepatitis Virus B Seropositive in the Patients with Cholangiocarcinoma: a Summary. Asian Pacific Journal of Cancer Prevention, 2005; 6(1): 27-28.
)